Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 7/20 | 0.52 |
| ▸ | BRAF | P15056 | 4/20 | 0.51 |
| ▸ | RAF1 | P04049 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.45 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365349 | 0.90 | KDR (0.52) | BRAFRAF1KDRPDE10ACSNK1D | |
| SCHEMBL4364801 | 0.79 | RAF1 (0.58) | FGFR2BRAFRAF1KDRPDE10A | |
| SCHEMBL4366196 | 0.75 | KDR (0.89) | KDR | |
| SCHEMBL23763480 | 0.75 | MEN1 (0.66) | KDRPDE10ACSNK1DCSNK1G2CSNK1A1 | |
| SCHEMBL4366959 | 0.73 | KDR (0.90) | FGFR2KDRPDE10AKIT | |
| SCHEMBL4366963 | 0.73 | KDR (0.59) | BRAFRAF1KDRPDE10ACSNK1D | |
| SCHEMBL13861960 | 0.73 | KDR (0.90) | FGFR2KDRPDE10AKIT | |
| SCHEMBL13861947 | 0.70 | KDR (0.61) | BRAFRAF1KDRPDE10ACSNK1D | |
| SCHEMBL4369261 | 0.69 | CSNK1A1 (0.54) | BRAFRAF1KDRPDE10ACSNK1D | |
| SCHEMBL4472020 | 0.69 | FGFR2 (1.00) | FGFR2KDRPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | FGFR2 1307/4885BRAF 612/4885RAF1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.